https://www.selleckchem.com/products/gcn2ib.html
nificantly higher in the ipragliflozin group. The current analysis showed ipragliflozin to be associated with significantly higher genital infection rates compared to placebo, whereas no significant difference was observed compared to the other adverse drug events in these patients with T2DM. In addition, hypoglycemia was also not significantly different following sensitivity analysis. The current analysis showed ipragliflozin to be associated with significantly higher genital infection rates compared to placebo, whereas no significant d
Like
Comment
Share
